May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Photodynamic therapy with verteporfin for idiopathic polypoidal choroidal vasculopathy. Preliminary results.
Author Affiliations & Notes
  • M. Mauget–Faysse
    Centre Ophtalmologique Rabelais, Lyon, France
  • M. Quaranta
    Centre Ophtalmologique Rabelais, Lyon, France
  • A. Leys
    Department of Ophthalomlogy, Leuven, Belgium
  • E. de La Marnierre
    Centre Ophtalmologique Rabelais, Lyon, France
  • Footnotes
    Commercial Relationships  M. Mauget–Faysse, None; M. Quaranta, None; A. Leys, None; E. de La Marnierre, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Mauget–Faysse, M. Quaranta, A. Leys, E. de La Marnierre; Photodynamic therapy with verteporfin for idiopathic polypoidal choroidal vasculopathy. Preliminary results. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:. To determine effects and safety of photodynamic therapy (PDT) with verteporphine in patients with exsudative idiopathic polypoidal choroidal vasculopathy (IPCV) in a prospective, non randomized study. Patients and Method: Consecutive patients, with history of recent visual loss and metamorphopsia, angiographically proved IPCV with retrofoveal localization of the polypoidal dilations or of the associated neovascular network were prospectively included and treated by PDT (standard protocol). Functional (best–corrected VA : ETDRS charts, Pelli–Robson contrast sensitivity (CS)), angiographic (fluorescein and ICG dyes), and OCT findings were assessed at baseline, 6 weeks, 3, 6, 9 and 12 months. Radial OCT scans were performed, at the same follow–up visits, across the fovea to measure retinal thickness at the foveal site. Treatment was performed every 3 months if polypoidal dilations were not occluded on FA/ICG and on OCT scans. Results: Thirty eyes (29 patients) were included : 12 women ( 41%) and 17 men ( 59%), mean age 67+/–8.6 years. Median follow–up was 9.7 months . Mean number of treatments given during the trial was 2.23+/–1. At inclusion, mean VA was 0.39+/–0.24. Mean CS was 1.27+/–0.31. On OCT scans, mean retinal thickness was 354+/–179 µm at the foveal site. All but 4 patients experienced an increase in VA at 6 weeks. This improvement continued until 3 months (0.5). At 6 months, mean VA lightly decreased (0.48) to increase again at 12 months (0.56). Age and number of treatments were correlated with a lower final VA (p<0.05). CS slowly and steadily improved until 9 months (1.37) and then stabilized. On OCT, retinal thickness decreased rapidly (–19.7%), then stabilized at 3 months and decreased again at 9 (–26.5%) and 12 months (–33%). Ocular adverse events were observed in three eyes: one had a severe but transient visual loss due to a foveal haemorrhage, immediately after PDT, one continued to present exudative polypoidal dilations and required laser photocoagulation treatment three months after the 3rd PDT, and one developed classic CNV, five months after the first PDT. Conclusion: Despite the short follow–up period, PDT for IPVC seems to achieve a rapid resolution of exudation correlated with an increase in VA and CS in most eyes, without significant harmful side effects. This clinical trial will end in September 2004 to confirm these positive preliminary results.

Keywords: choroid: neovascularization • photodynamic therapy • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×